secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lomond Therapeutics Holdings, Inc. (—)
CIK:        0001900520
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001213900-26-003905
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lomond terminates menin inhibitor license from Bala; receives 3.5% stake
------------------------------------------------------------------------

- Terminated license agreement with Bala for an early-stage menin inhibitor (AML) due to crowded competitive landscape.
- Company had spent ~$600K on development; $1.2M deferred payment obligation cancelled with termination.
- Received 111,585 shares of Bala common stock (~3.5% of fully diluted cap) as consideration for prior expenditure.
- All licensed IP reverts to Bala; no further development or payments required.
- No activities or third-party agreements had been undertaken under the license.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1900520/000121390026003905/0001213900-26-003905-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1900520/000121390026003905/ea0269967-8k_lomond.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-003905

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer